Alnylam starts dosing RNAi therapy; Thermo Fisher Scientific broadens delivery tech with fragment library;

> Alnylam Pharmaceuticals has started dosing patients in a Phase I study of the RNAi therapy ALN-TTR01, which uses Tekmira's leading lipid nanoparticle delivery technology. Release

> Thermo Fisher Scientific has added the Maybridge Ro3 Diversity Fragment Library to its offerings, expanding its drug delivery technology offerings. Story

> Silence Therapeutics says that it has expanded its RNA silencing IP portfolio with the issuance of a new patent. Release

> Biocompatibles International has acquired patents protecting its bead products in a $4.5 million deal with Biocure. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.